pharmaphorum7d
Boost to Enhertu's prospects as FDA clears Roche diagnostic
Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...
Cure Today1mon
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
pharmaphorum2y
AZ gets FDA nod for Enhertu in first HER2-low cancer
In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...
Clinical Trials Arena on MSN18d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall ...